Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.

@article{Ruocco2012SuppressingTC,
  title={Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.},
  author={Maria Grazia Ruocco and Karsten A. Pilones and Noriko Kawashima and Michael Cammer and Julie Tzu-Ling Huang and James S. Babb and Mengling Liu and Silvia Chiara Formenti and Michael L. Dustin and Sandra Demaria},
  journal={The Journal of clinical investigation},
  year={2012},
  volume={122 10},
  pages={3718-30}
}
A promising strategy for cancer immunotherapy is to disrupt key pathways regulating immune tolerance, such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4). However, the determinants of response to anti-CTLA-4 mAb treatment remain incompletely understood. In murine models, anti-CTLA-4 mAbs alone fail to induce effective immune responses to poorly immunogenic tumors but are successful when combined with additional interventions, including local ionizing radiation (IR) therapy. We employed… CONTINUE READING